FDA Agrees to Expanded Access Program for the BioVentrix(R) Revivent TC(R) System for the Treatment of Ischemic Heart Failure

Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 -- (Healthcare Sales & Marketing Network) -- BioVentrix®, Inc., a privately held medical device company focused on the development of les... Devices, Cardiology, FDA BioVentrix, Revivent TC System, heart failure

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2047889

Source: HSMN NewsFeed - January 24, 2023 Category: Pharmaceuticals Source Type: news